Proprietary platform
A shared technology base applied to paw and footwear treatment, with self-contained and building-integrated configurations.
Investor Relations
Join the next phase of HYGEN KLINX.
A proprietary hardware platform for automated paw and footwear hygiene, developed through the PET KLINX and HOME KLINX ecosystems.
HYGEN KLINX is opening discussions with selected financial investors and strategic partners to support product development, validation and market entry.
ECONOMIC MODEL · 5Y BASE SCENARIO
A structure designed to generate industrial value.
The model combines proprietary hardware and consumables. In the Business Plan base scenario, the weighted average gross margin is approximately 59.4%.
59.4%modelled average
gross margin
gross margin
59.4% Gross margin40.6% Direct costsPre-commercial projection, not historical performance or a return guarantee.
Investment thesis
A new category of automated hygiene.
Organic residue, microorganisms, dust and substances from outdoor surfaces can reach indoor spaces on soles and paws. HYGEN KLINX develops treatment at the entrance designed to make this routine controlled and repeatable, with performance to be validated.
Complementary markets
Premium consumer, pet care, advanced residential, hospitality and Building/B2B opportunities to be validated progressively.
Diversified revenue
Hardware, consumables, support and potential industrial partnerships or licensing models over the medium to long term.
Market opportunity
A broad, measurable and cross-market context.
HYGEN KLINX sits at the intersection of the home, pet care and built environments. Public data does not replace a proprietary TAM, but it shows the scale of the pools in which the platform can be validated.
HOME KLINX · CORE MARKET UNIVERSE≈335.8m
households across the European Union and United States
PET KLINX · CORE MARKET UNIVERSE≈125.8m
dog-owning households across the European Union and United States
HOME · PRELIMINARY TARGET POOL≈21.4m
households selected by the research model’s theoretical screening; purchase intent still needs measurement.
PET · THEORETICAL 1% SCREENING≈1.258m
households across the Core Market Universe; an exploratory base, not a commercial forecast.
01
Two recurring use casesPaws and footwear share the same transfer problem into indoor environments.
02
One extensible platformThe same architecture supports consumer products and building-integrated configurations.
03
Multiple routes to marketDirect sales, specialist channels, Building and industrial partnerships can be validated in stages.
Business Plan method and sources. HOME combines 203.1 million EU households (Eurostat, 2025) and 132,737,146 US households (U.S. Census Bureau, ACS 2024). PET is a derived value: an EU proxy of approximately 54.8 million, applying the 27% FEDIAF Total EU dog-ownership share (2023 data) to the EU household base; plus approximately 71 million US dog-owning households (APPA, 2025). The proxy combines bases from different years and is not a direct count of EU dog-owning households. Italy is already included in the EU figure. These are pre-commercial universes and screening values, not SAM, SOM, customers, orders or sales.
Business model architecture
Multiple value layers, one platform.
The structure combines two product families, complementary configurations and progressive commercial routes without relying on a single application.
PET KLINX and HOME KLINX
Standalone and Building across both ecosystems
Hardware, consumables and services or partnerships
Consumer/B2C and Building/B2B
CoreProprietary platform
→ApplicationsPET + HOME
→ChannelsConsumer + Building
A pre-commercial strategic architecture to be validated progressively. The figures describe the model structure, not customers, orders, revenue or forecasts.
Where we are
From protected concept to validation.
The project is pre-commercial. The strategy is to reduce technical and commercial risk through verifiable milestones before committing capital to scale.
View development01Intellectual property2 patents.
02Engineering developmentConceptual architectures defined and technical work in progress.
03Product platformPET and HOME, each in Standalone and Building configurations.
04Stage-gate roadmapDesign, prototyping, testing, pre-series and industrialisation.
05Economic modelFive-year financial model and milestone-based funding strategy.
06Market infrastructureBrand, digital presence and market research supporting commercial validation.
Platform architecture
Four configurations, one ecosystem.
Standalone product lines enable direct market validation. Building configurations extend the same logic to residential, hospitality and other professional settings.
Shared proprietary foundation1 platform
A technology core to be validated in stages without publishing confidential architectures or details.
PET · 01StandalonePlanned first path to validation.
HOME · 02StandaloneApplication dedicated to footwear.
PET · 03BuildingConfiguration for shared contexts.
HOME · 04BuildingIntegration into built access points.
Automated paw hygiene.
The first configuration planned for technical and commercial validation.
Discover PET KLINXAutomated footwear hygiene.
A consumer solution designed for domestic and premium spaces.
Discover HOME KLINX
BUILDING · B2B
Building integration.
PET and HOME configurations for residential buildings, hotels, hospitals, airports, infrastructure and high-traffic shared access points.
Discover Building solutions
Founder
Giorgio Serantoni
Founder & CEO
He has led HYGEN KLINX from the initial concept through early physical experimentation, IP protection and structured engineering development. He coordinates product vision, market research, business and financial modelling, brand development, specialist partners and fundraising strategy as the project moves toward validation and industrialisation.
Product vision & developmentIP & project coordinationBusiness & financial modellingFundraising & go-to-market
FROM IDEAS TO REALITY
From concept to engineering development.
Early physical experimentation helped translate the initial concept into concrete functional requirements that now underpin the platform’s engineering development.
CONCEPT
Ideation, problem analysis and definition of solution principles.
PHYSICAL EXPERIMENTATION
Preliminary checks on key functional principles and definition of requirements.
ENGINEERING DEVELOPMENT
Design, engineering and preparation for the industrialisation phase.
Detailed technical documentation is available exclusively as part of due diligence and subject to appropriate confidentiality arrangements.
Next phase
Capital linked to verifiable outcomes.
Target Seed round€250,000Transaction being structured
HYGEN KLINX is opening a target €250,000 Seed round to support the next stage of the project without building an oversized structure too early. Equity, valuation and economic terms are discussed exclusively in a confidential setting with qualified counterparties.
The complete Business Plan, confidential technical details and transaction terms are shared progressively during discussions.
Prototype and technical validation
Turn the conceptual architecture into verifiable subsystems and prototypes.
Preliminary industrialisation
Bill of materials, design for manufacturing, suppliers and pre-series preparation.
Commercial validation
Market testing, pricing, channels, acquisition and collection of observed data.
Intellectual property and compliance
Advance the IP strategy and prepare the certification pathway.
Milestone-based allocationaggregated percentages · no product pricing
Product and engineering24%
Technical proof and industrialisation18%
Market validation18%
Pilot and pre-series14%
IP and PCT pathway8%
Governance, contracts and reserve18%
Aggregated view derived from the capital deployment plan. Individual items may be reallocated as stage-gate evidence emerges and do not constitute a public offer.
Investor process
A selective and confidential dialogue.
Application
Submit essential information through the investor form.
Qualification
Review of profile, interest and strategic alignment.
Teaser and call
Initial materials and a direct discussion about the project.
NDA and Data Room
Progressive access to the Business Plan, financial model and confidential documents.
Assessment
Due diligence and discussion of a potential partnership.
Investor enquiry
Let’s discuss the opportunity.
Complete the form to request an initial conversation. We will review the profile and share the appropriate materials as the discussion progresses.
Direct and confidential contactMaterials shared progressivelyNo newsletter or generic communications
This page is provided solely for information and to initiate discussions. The stated fundraising target does not constitute a public offer, solicitation to invest, financial recommendation or commitment to complete a transaction. Any potential discussion will be subject to dedicated assessment, documentation and professional review.